

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

1.-12. (cancelled)

13. (withdrawn) A topical composition comprising:

(A) an aqueous *Curcuma* extract; and

(B) a pharmaceutically acceptable carrier for topical administration.

14. (withdrawn) The topical composition according to Claim 13, wherein the composition further comprises an extract obtained by extracting *Curcuma* rhizomes using a solubilizing lipophilic compound.

15. (withdrawn) The topical composition according to Claim 14, wherein said compound is ethanol.

16. (withdrawn) The topical composition according to Claim 13, wherein said *Curcuma* extract is an extract of *Curcuma longa* rhizomes.

17. (new) A method for treating a mammal having a proliferative disease characterized by skin inflammation comprising topically administering to said mammal an effective amount of a pharmaceutical composition comprising an aqueous *Curcuma* extract, and then subjecting said mammal to ultraviolet radiation.

18. (new) The method of claim 17, wherein said proliferative disease is selected from the group consisting of psoriasis, lichen, atopic dermatitis, granuloma annulare, and mycosis fungoides.

19. (new) The method of claim 17, further comprising orally administering to said mammal an effective amount of an aqueous *Curcuma* extract.

20. (new) The method of claim 17, wherein said pharmaceutical composition comprises a 2% *Curcuma longa* aqueous extract.

21. (new) The method of claim 17, wherein said pharmaceutical composition is administered for 7 or 14 days.

22. (new) The method of claim 19, wherein 100 mg/day of an aqueous *Curcuma* extract is orally administered.

23. (new) The method of claim 17, wherein said ultraviolet radiation is ultraviolet A.
24. (new) The method of claim 17, wherein said mammal has psoriasis.
25. (new) The method of claim 24, wherein said method results in a reduction of skin lesions.
26. (new) The method of Claim 17, wherein said proliferative disease is characterized by production of IL-8 or IL-6.
27. (new) The method of claim 17, wherein said *Curcuma* extract is an extract of *Curcuma longa* rhizomes.
28. (new) A method for treating a mammal having a proliferative disease characterized by skin inflammation comprising:
- topically administering to said mammal an effective amount of a pharmaceutical composition comprising a hydro alcoholic *Curcuma* extract,
- irradiating said mammal with a lamp that radiates visible light having a spectrum of 400-550 nanometers, and
- subjecting said mammal to ultraviolet radiation.

29. (new) The method of claim 28, wherein said proliferative disease is selected from the group consisting of psoriasis, lichen, atopic dermatitis, granuloma annulare, and mycosis fungoides.

30. (new) The method of claim 28, wherein said extract comprises a 2% *Curcuma longa* hydro alcoholic extract.

31. (new) The method of claim 28, wherein said method is performed weekly.

32. (new) The method of claim 28, wherein said mammal has psoriasis.

33. (new) The method of claim 32, wherein said method results in a reduction of skin lesions.

34. (new) The method of claim 28, wherein said *Curcuma* extract is an extract of *Curcuma longa* rhizomes.